ALLO - Allogene Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ALLO

ALLOGENE THERAPEUTICS, INC.

NASDAQ

$1.40

▼ DOWN 2.10% (-0.03)

KEY STATISTICS

Market Cap$481.49 M

52w High$4.46

52w Low$1.04

Dividend Yield—

Frequency—

P/E-2.09

Volume7.97M

Shares Out.345.15M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Zachary Roberts

COMPENSATION 2026

Salary$724,000

Stock Awards$1,071,218

Incentive Plan Pay$400,010

All Other Comp.$14,217

Total$6,136,093

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 11, 2018

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

151

PRICE TARGET

Target High$9.00

Target Low$3.85

Target Median$6.42

Target Consensus$6.43

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$2.50K

NOV

THU

ETFS HOLDING THIS STOCK

ETFS HOLDING

107

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

46.79%

HOLDERS

289

TOP 8 OF 289 · RANKED BY POSITION SIZE

Blackrock, Inc.

30.1M sh

$62.71M

Frazier Life Sciences Management, L.P.

Tpg Group Holdings (Sbs) Advisors, Inc.

PRICE

$1.40 ▼ DOWN 2.10% (−$0.03)

About Allogene Therapeutics, Inc.

https://www.allogene.com ↗

Allogene Therapeutics develops and commercializes genetically engineered allogeneic CAR T cell therapies for cancer, with multiple candidates in clinical trials targeting various hematologic and solid tumors.

INDUSTRY

Biotechnology

A PRODUCT ALLOGENE THERAPEUTICS, INC. IS KNOWN FOR

cemacabtagene ansegedleucel (cema-cel)

Cema-cel is an allogeneic, off-the-shelf CAR T-cell therapy in Phase 2 for large B-cell lymphoma, aiming to provide a rapid, frontline treatment option through its innovative ALPHA3 trial.

COMPETITORS

COMPETITOR

Allogene Therapeutics in 2025

SENTIMENT: + POSITIVE

REGULATORY · Q2-Q3 2025

Allogene Therapeutics Announces Positive Data for ALLO-316 in Kidney Cancer at ASCO and Aligns with FDA on Pivotal Trial Design

In Q2 2025, Allogene Therapeutics presented updated Phase 1b data for its solid tumor candidate, ALLO-316, in renal cell carcinoma at the American Society of Clinical Oncology (ASCO) Annual Meeting. Following the data presentation, the company announced in August that it had aligned with the U.S. Food and Drug Administration (FDA) on a pivotal trial design, signaling a clear path forward for the therapy and sparking discussions around potential partnerships to advance the program.

RESTRUCTURING · MAY 2025 · IN PROGRESS

Allogene Therapeutics Restructures to Extend Cash Runway, Delaying Key Clinical Readouts

In a significant strategic move to preserve capital, Allogene Therapeutics announced a 28% workforce reduction and a cost-realignment program. This decision, which follows a 22% layoff in the previous year, is designed to extend the company's financial runway into the second half of 2027, prioritizing key clinical programs amidst a challenging macroeconomic environment.